we are helping to transform the treatment of patients in four key areas: biosurgery, orthopaedics (sports medicine/spine), dental and cardiac in pipeline porcine (x) human (h) biosurgery cardiac orthopaedic [thicker dermis] navigating the report for further information within this document and relevant page numbers scan the qr code to learn more about our dcell technology in this short video or visit www.tissueregenix.com/ media/innovations-in-soft-tissue- regenerative-medical-technology scan the qr code to learn more about cellright technologies in this short video or visit www.tissueregenix.com/ media/healing-skeletal-defects- through-regenerative-medicine ticker aim: trx www.tissueregenix.com who we are our vision to establish tissue regenix as a leader in the science and innovation of regenerative medicine and become clinicians’ partner of choice to meet growing clinical needs, transform patient care and deliver favourable health economic outcomes. dcell ® tissue strategy learn more about us overview highlights 01 chairman’s statement 02 corporate structure 03 who are cellright technologies? z group loss for the year of £9.4m — improvement from £9.9m (11 months to december 2016) — investment into research and development continues. with our augmented, established product portfolio generating a growing level of sales, we have identified key development assets to focus our commercial resources behind, and we are confident that following final product validation and transfer of manufacturing in-house, the newly focused strategy will drive significant shareholder returns. he has had an extensive career including smith & nephew and more recently, sanofi biosurgery based in boston, massachusetts. chairman’s statement we have completed a transformative acquisition, delivered 46% growth in dermapure ® sales and expanded the clinical applications of our products to access new healthcare professionals whilst successfully progressing integration activities. john samuel, executive chairman ticker aim: trx www.tissueregenix.com 02 for more information on our performance see pages 07 to 18 a tissue regenix group company cellright technologies san antonio, texas cellright technologies is based at a 13,650 sq ft fda accredited facility in university city, san antonio. integration highlights { growth momentum of cellright portfolio maintained { dermapure ® manufacturing transfer on track { financial control & governance framework implemented { one company customer service and back office established { initial cross-selling opportunities being realised. adoption of new technologies will be dependent on delivering better patient outcomes while lowering the total treatment cost. overview tissue regenix group plc annual report and accounts for the year ended 31 december 2017 05 what is regenerative medicine? dcell ® technology provides an enhanced healing environment, in terms of both natural, tissue-specific physical structure and bio-mechanical properties. with its first full year of sales, controlled joint venture gbm-v increased revenue by 8 fold to £1.1m. with adoption by the acute surgical and wound reconstruction markets, due to its impressive clinical outcomes with a single application, dermapure ® has seen significant uptake in the orthopaedic trauma and urogynaecology arenas where treatment innovation has been in high demand. having identified an opportunity in this market, we have signed an exclusive distributor agreement with arms medical, a specialist urogynaecology distributor in the united states to maximise this opportunity, leveraging their strong relationships with kols and surgeons. for more on our cardiac division and gbm-v see pages 16-17 orthopaedics and dental - cellright technologies cellright technologies officially became a part of the tissue regenix group in august 2017. based around a proprietary processing technology ‘biorinse ® ’, cellright produces a portfolio of inductive, verified bone matrices in different physical forms to address clinical indications in the orthopaedic, spine, dental and general surgery procedures. in october they commenced the production of amnioworks ® , an advanced wound care product derived from human amniotic membrane. alongside this, additional sizes of their frozen and freeze dried wound care product matrix iq were released to address larger surgical site procedures. fundamental to this was the announcement of a long-term, multi-year distribution agreement with arthrex, inc. for cellright’s osteobiologic products. sales in both cellright and biosurgery have had a strong start to the year, including shipments under two significant distributor agreements. commercial execution 2 3 4 5 strategic partnerships clinical evidence geographic expansion portfolio development ticker aim: trx www.tissueregenix.com 10 our strategy for more information on our technologies see page 06 strategic objectives the group’s strategic objectives are targeted to meet its vision of becoming a global leader in regenerative medicine, addressing critical and growing clinical needs, transforming patient care and providing favourable health economic outcomes, in order to build a business capable of generating attractive long term results for investors. integra tion cellright integration into the tissue regenix group { implementation of shared services and back office functions { standardized operational reporting. business review 2017 was another successful year for dermapure ® as we continue to establish momentum and sales traction. progressing from traditional wound care clinical settings to surgical applica tions is a na tural evolution for dermapure ® . 2016e 2017e 2018e 2019e 2020e 1.09bn 0.9bn 1.19bn 1.29bn 1.41bn 1.52bn 2015 collagen/active dressings s/d amniotic tissue/allografts s/d dermal allografts s/d xenographs & other s/d cell-based bioengineering topical delivery/drug us wound biologics market forecast 2015-2020e cagr 9.8% strategic report tissue regenix group plc annual report and accounts for the year ended 31 december 2017 13 financial overview investment continued in the period with development costs of £894k (11 months to december 2016: £1,221k). with ongoing business development in the us, initial costs around a fda approved pre-clinical trial for orthopure™ xt have been incurred. with positive clinical data being reported at 1 year we have developed additional indications to also encompass extra-articular knee reconstruction procedures. throughout the year we also worked closely with our biosurgery division to introduce dermapure ® into the orthopaedic soft tissue market where it could be used as a suitable option for tendon reinforcement, rotator cuff repair, and other surgical procedures. historically, we have commercialised our products through a network of distributors and white label (oem) agreements. jesus hernandez, ceo, cellright technologies strategic report divisional overview cellright technologies since joining the tissue regenix group in august 2017, we ha ve made significant progress against our commercial milestones, and delivered against our revenue expecta tion for the period. his impressive clinical results also play a significant role in the eu regulatory application process currently ongoing. with the search for an ideal pericardial valve ongoing, there is huge interest from particularly paediatric cardiac surgeons in this potential business development. this patch could also be used as a springboard for developing biological surgical, transcatheter and sutureless heart valves. working closel y with our new team a t cellright technologies, and our research partners around the world, we are uniquel y positioned to bring to market a portfolio of human tissue derived cryo-preserved and decellularized applica tions. this ensures that we do not rely on a single source provider and can ensure to meet the increasing demand for suitable donated tissue. our facility is spit over separate buildings meaning that an incident can be contained within one area and should not affect all business activities. the group operates a strictly controlled quality management system, and has in-house experts to ensure compliance with all regulatory requirements. tissue regenix group plc annual report and accounts for the year ended 31 december 2017 21 strategic report tissue regenix’s vision to become a leader in regenerative medicine is underpinned by its core values to maintain a sustainable, ethical and responsible company. steve was appointed ceo of tissue regenix in november 2017 having served as a non-executive director for four years. he is also a non- executive director of bb healthcare investment trust, listed on the london stock exchange, since december 2016. randeep has been involved in a number of start-up and early stage companies both personally and as an investor. we also monitor any existing and potential partners to ensure that they align with our company values. it is the company’s policy that executive directors should have contracts with an indefinite term providing for a maximum of six months’ notice. as at 31 december 2017 none of the performance conditions had been met and no options were eligible for exercise. as at 31 january 2016 none of the performance conditions had been met and no options were eligible for exercise. as at 31 december 2017 none of the performance conditions had been met and no options were eligible for exercise. the shares were all acquired pursuant to certain conditions set out in joint owned equity agreements (“joes”). ticker aim: trx www.tissueregenix.com 36 consolidated statement of changes in equity for the year ended 31 december 2017 attributable to equity holders of the parent share capital £000 share premium £000 merger reserve £000 reverse acquisition reserve £000 reserve for own shares £000 share based payment reserve £000 retained earnings deficit £000 total £000 non- controlling interests £000 total equity £000 at 31 january 2016 3,801 50,461 10,884 (7,148) (831) 946 (36,791) 21,322 (83) 21,239 loss for the period – – – – – – (9,786) (9,786) (126) (9,912) other comprehensive expense – – – – – – (1) (1) – (1) loss and total comprehensive expense for the period – – – – – – (9,787) (9,787) (126) (9,913) share based payment expense – – – – – 210 – 210 – 210 at 31 december 2016 3,801 50,461 10,884 (7,148) (831) 1,156 (46,578) 11,745 (209) 11,536 loss for the period – – – – – – (9,221) (9,221) (200) (9,421) other comprehensive expense – – – – – – (614) (614) – (614) loss and total comprehensive expense for the period – – – – – – (9,835) (9,835) (200) (10,035) issue of shares 2,000 38,000 – – – – – 40,000 – 40,000 cost of issue of new equity – (2,318) – – – – – (2,318) – (2,318) exercise of share options 54 255 – – – – – 309 – 309 share based payment expense – – – – – 30 – 30 – 30 at 31 december 2017 5,855 86,398 10,884 (7,148) (831) 1,186 (56,413) 39,931 (409) 39,522 financials tissue regenix group plc annual report and accounts for the year ended 31 december 2017 37 consolidated statement of financial position as at 31 december 2017 notes 31 december 2017 £000 31 december 2016 £000 assets non-current assets property, plant and equipment 9 2,994 1,087 intangible assets 10 19,305 550 total non-current assets 22,299 1,637 current assets inventory 11 2,872 661 trade and other receivables 12 4,168 3,130 cash and cash equivalents 13 16,423 8,173 total current assets 23,463 11,964 total assets 45,762 13,601 liabilities non-current liabilities other payables 14 (635) – total non-current liabilities (635) – current liabilities trade and other payables 14 (4,781) (2,065) total current liabilities (4,781) (2,065) provisions deferred tax 15 (824) – total provision (824) – total liabilities (6,240) (2,065) net assets 39,522 11,536 equity share capital 17 5,855 3,801 share premium 17 86,398 50,461 merger reserve 17 10,884 10,884 reverse acquisition reserve 17 (7,148) (7,148) reserve for own shares 18 (831) (831) share based payment reserve 20 1,186 1,156 retained earnings deficit 18 (56,913) (46,578) equity attributable to equity holders of parent 39,931 11,745 non-controlling interests (409) (209) total equity 39,522 11,536 approved by the board of directors and authorised for issue on 26 march 2018. steven couldwell chief executive officer company number: 5969271 ticker aim: trx www.tissueregenix.com 38 consolidated statement of cash flows for the year ended 31 december 2017 notes year to 31 december 2017 £000 11 months to 31 december 2016 £000 operating activities operating loss (10,816) (11,060) adjustment for: depreciation of property, plant and equipment 9 482 301 amortisation of intangible assets 19 225 – share based payments 20 30 210 research tax credit received 1,541 319 operating cash outflow (8,538) (10,230) (increase) in inventory 11 (503) (597) (increase) in trade and other receivables (783) (90) increase in trade and other payables 38 106 net cash outflow from operations (9,786) (10,811) investing activities interest received 6 47 114 purchases of property, plant and equipment 9 (130) (487) capitalised development expenditure 10 (93) (550) acquisition of subsidiary 16 (19,945) – net cash (outflow) from investing activities (20,121) (923) financing activities proceeds from issue of share capital 17 37,682 – proceeds from exercised share options 309 – net cash inflow from financing activities 37,991 – increase/(decrease) in cash and cash equivalents 8,084 (11,734) foreign exchange translation movement 166 – cash and cash equivalents at start of period 8,173 19,907 cash and cash equivalents at end of period 16,423 8,173 financials tissue regenix group plc annual report and accounts for the year ended 31 december 2017 39 notes to the financial statements for the year ended 31 december 2017 1) basis of preparation the financial statements of tissue regenix group plc are audited consolidated financial statements for the year ended 31 december 2017. these include audited comparatives for the 11 month period ended 31 december 2016. the group financial statements consolidate the financial statements of tissue regenix group plc and the entities it controls, being its subsidiaries and its joint venture interest. they are subsequently measured at amortised cost using the effective interest rate method, less any provision for impairment. incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction. the value in use calculations, which are made on an annual basis for goodwill, or when there is an indicator of impairment for tangible and other intangible fixed assets, determine whether there is any impairment to the carrying value of assets arising from business combinations. the future aggregate minimum lease and service charge payments under non-cancellable operating leases are as follows: as at 31 december 2017 £000 as at 31 december 2016 £000 land and buildings: amounts due within one year 85 64 amounts due between 1 – 5 years 61 – total 146 64 20) share based payments share options and shares held in employee benefit trust (“ebt”) the company operates a share option plan, under which certain employees have been granted options to subscribe for ordinary shares. the shares were acquired pursuant to certain conditions, set out in jointly owned equity agreements (“joes”). any other share options and employee interests in jointly owned ebt shares which are not exercised within 10 years from the date of grant will expire. financials tissue regenix group plc annual report and accounts for the year ended 31 december 2017 59 company statement of changes in equity for the year ended 31 december 2017 attributable to the equity holders of the company share capital £000 share premium £000 merger reserve £000 share based payment reserve £000 retained earnings reserve £000 total £000 at 31 january 2016 3,801 50,461 10,884 873 (7,527) 58,492 total expense and other comprehensive loss for the period – – – – (1,701) (1,701) share based payment expense – – – 210 – 210 at 31 december 2016 3,801 50,461 10,884 1,083 (9,228) 57,001 total expense and other comprehensive loss for the period – – – – (1,793) (1,793) issue of shares 2,000 40,000 – – – 40,000 cost of issue of new equity – (2,318) (2,318) share options exercised 54 255 – – – 309 share based payment expense – – – 30 – 30 at 31 december 2017 5,855 86,398 10,884 1,113 (11,021) 93,229 ticker aim: trx www.tissueregenix.com 60 company statement of financial position as at 31 december 2017 notes at 31 december 2017 £000 at 31 december 2016 £000 assets non-current assets investments c3 12,922 12,922 total non-current assets 12,922 12,922 current assets trade and other receivables c4 250 63 intercompany loan balance c5 64,390 36,531 cash and cash equivalents 15,949 7,819 80,589 44,413 total assets 93,511 57,335 liabilities current liabilities trade and other payables c6 (384) (334) total liabilities (384) (334) net assets 93,127 57,001 equity share capital 17 5,855 3,801 share premium 17 86,398 50,461 merger reserve 17 10,884 10,884 share based payment reserve 20 1,113 1,083 retained earnings deficit (11,123) (9,228) total equity 93,127 57,001 approved by the board of directors and authorised for issue on 26 march 2018. steven couldwell chief executive officer company number: 5969271 financials tissue regenix group plc annual report and accounts for the year ended 31 december 2017 61 company statement of cash flows for the year ended 31 december 2017 ticker aim: trx www.tissueregenix.com 62 notes year to 31 december 2017 £000 11 months to 31 december 2016 £000 operating activities loss before interest and tax (1,837) (1,815) adjustment for non-cash items: share based payments 20 30 210 operating cash outflow (1,807) (1,605) (increase) in trade and other receivables (187) (3) (decrease)/increase in trade and other payables (52) 16 net cash absorbed by operations (2,046) (1,592) investing activities interest received 44 114 loan to subsidiary undertaking c5 (27,859) (10,301) net cash used in investing activities (29,861) (10,187) financing activities proceeds from issue of share capital 17 37,682 – proceeds from exercise of share options 17 309 – net cash generated from financing activities 37,991 – increase/(decrease) in cash and cash equivalents 8,130 (11,779) cash and cash equivalents at start of period 7,819 19,598 cash and cash equivalents at end of period 15,949 7,819 notes to the company information for the year ended 31 december 2017 financials tissue regenix group plc annual report and accounts for the year ended 31 december 2017 63 c1. accordingly, where material, recoverability has been tested against value in use by reference to business projections. normal system timings and limitations will therefore apply in relation to the input of crest proxy instructions. notice of annual general meeting continued ticker aim: trx www.tissueregenix.com 68 directors john samuel (chairman) steven couldwell (chief executive officer) jonathan glenn (non-executive director) alan miller (non-executive director) randeep singh grewal (non-executive director) shervanthi homer-vanniasinkam (non-executive director) company secretary paul below company website www.tissueregenix.com company number 05969271 (england & wales) registered office registrar unit 1 & 2 link asset services astley way the registry astley lane industrial estate 34 beckenham road leeds beckenham west yorkshire kent ls26 8xt br3 4tu auditor legal adviser kpmg llp dla piper uk llp 1 sovereign square princes exchange sovereign street princes square leeds leeds ls1 4da ls1 4by nominated adviser and broker jefferies international ltd vintners place 68 upper thames street london ec4v 3bj tissue regenix group plc annual report and accounts for the year ended 31 december 2017 ibc directors and officers financials tissue regenix group plc unit 1 and 2 astley way astley lane industrial estate swillington leeds ls26 8xt www.tissueregenix.com tissue regenix group plc annual report and accounts for the year ended 31 december 2017